Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373

ClinicalTrials.gov

Author's Posts:
Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers
Condition:   MUC17-positive Solid Tumors
Intervention:   Drug: AMG 199
Sponsor:   Amgen
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 15, 2021 / by / in
Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic Cancer
Conditions:   Pancreatic Cancer;   Pancreatic Neoplasms;   Adenocarcinoma of the Pancreas
Interventions:   Procedure: 2 passes during EUS-guided fine needle biopsy;   Procedure: 3 passes during EUS-guided fine needle biopsy
Sponsor:   Orlando Health, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 15, 2021 / by / in
EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement
Condition:   Malignant Pleural Neoplasm
Interventions:   Drug: Lidocaine;   Drug: Liposomal Bupivacaine;   Other: Questionnaire Administration
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 15, 2021 / by / in
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: ERAS-007;   Drug: Encorafenib;   Drug: Cetuximab;   Drug: Palbociclib
Sponsor:   Erasca, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 15, 2021 / by / in
Open-Label Study to Evaluate Mirvetuximab Soravtansine in Cancers With High Folate Receptor-Alpha Expression
Conditions:   Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention:   Drug: Mirvetuximab soravtansine
Sponsors:   ImmunoGen, Inc.;   IQVIA Biotech
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 14, 2021 / by / in
Wet Heparinized Suction for Abdominal Cancer
Conditions:   Cancer of Pancreas;   Cancer of Stomach;   Cancer of Esophagus;   Cancer of Liver;   Cancer
Interventions:   Other: wet heparinzed suction;   Other: Microsieve;   Other: No heparin flush;   Other: No microsieve
Sponsor:   University Hospitals Cleveland Medical Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 14, 2021 / by / in
Management of Symptomatic Gastric Sleeve Stenosis After Laparoscopic Sleeve Gastrectomy
Condition:   Gastric Stenosis
Interventions:   Procedure: Endoscopic pneumatic balloon dilation;   Procedure: Gastric peroral endoscopic myotomy (G-POEM);   Procedure: Roux-en-Y gastric bypass (RYGB)
Sponsor:   Johns Hopkins University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 11, 2021 / by / in
People of Color and Dermatology: A Deeper Look at Patients’ Perceptions of Care and the Need for Greater Diversity in Dermatology
Condition:   Dermatology
Intervention:  
Sponsor:   Northwestern University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 11, 2021 / by / in
IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors
Conditions:   Advanced Endometrial Carcinoma;   Advanced Head and Neck Squamous Cell Carcinoma;   Advanced Malignant Solid Neoplasm;   Advanced Melanoma;   Advanced Ovarian Clear Cell Adenocarcinoma;   Chondrosarcoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8;   Refractory Endometrial Carcinoma;   Refractory Head and Neck Squamous Cell Carcinoma;   Refractory High Grade Ovarian Serous Adenocarcinoma;   Refractory Melanoma;   Refractory Ovarian Clear Cell Adenocarcinoma;   Stage III Ovarian Cancer AJCC v8;   Stage III Uterine Corpus Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Uterine Corpus Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Uterine Corpus Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Uterine Corpus Cancer AJCC v8;   Stage IIIC1 Uterine Corpus Cancer AJCC v8;   Stage IIIC2 Uterine Corpus Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Uterine Corpus Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Uterine Corpus Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Uterine Corpus Cancer AJCC v8
Interventions:   Drug: Glutaminase Inhibitor IPN60090;   Biological: Pembrolizumab
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 11, 2021 / by / in
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Conditions:   Ovarian Cancer;   Ovarian Neoplasms;   Ovarian Carcinoma;   Endometrial Cancer;   Colorectal Cancer;   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma;   Gastric Adenocarcinoma;   TNBC – Triple-Negative Breast Cancer;   Triple Negative Breast Cancer;   Cholangiocarcinoma;   Bile Duct Cancer;   Colon Cancer;   Colon Cancer Stage;   Colon Neoplasm;   Colon Adenocarcinoma;   Colon Rectal Cancer;   Colon Cancer Liver Metastasis;   Colorectal Neoplasms;   Colorectal Carcinoma;   Colorectal Adenocarcinoma;   Colorectal Cancer Metastatic;   Colorectal Cancer Stage IV;   Rectum Cancer;   Rectum Neoplasm;   Rectum Carcinoma;   Rectal Cancer;   Rectal Neoplasms;   Rectal Adenocarcinoma;   Rectal Cancer Stage;   Rectal Cancer Metastatic;   Rectal Cancer Stage III;   Esophagus Cancer;   Esophageal Cancer;   Esophageal Neoplasms;   Gastric Cancer Stage;   Breast Cancer;   Breast Neoplasm;   Breast Adenocarcinoma;   Breast Cancer Stage IV;   Breast Cancer Stage;   Breast Cancer Metastatic;   Breast Cancer Invasive;   Triple Negative Breast Neoplasms;   Intrahepatic Cholangiocarcinoma;   Intrahepatic Cholangiocarcinoma Recurrent;   Hilar Cholangiocarcinoma;   Distal Cholangiocarcinoma;   Ovary Cancer;   Ovary Neoplasm;   Ovary Disease;   Ovary Metastasis;   Ovarian Diseases;   Ovarian Cancer Stage;   Ovarian Epithelial Cancer;   Ovarian Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Neoplasm Epithelial;   Ovarian Cancer Recurrent;   Endometrial Diseases;   Endometrial Adenocarcinoma;   Endometrial Carcinosarcoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrioid Adenocarcinoma;   Endometrial Neoplasms;   Endometrial Cancer Recurrent;   Endometrioid Tumor;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention:   Drug: ELU001
Sponsor:   Elucida Oncology
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 10, 2021 / by / in